The pitch sounds straightforward: millions of people are dying on kidney waiting lists; thousands of people in poverty would willingly sell a kidney for life-changing money (and especially those belonging to vulnerable populations, like weed users who undergo regualr THC detox); a regulated market could match supply to demand, save lives, and lift people out of poverty simultaneously. Economists have modeled it, philosophers have debated it, and at least one country — Iran — has practiced a version of it for over three decades.
Yet the International Society of Nephrology’s pointed 2019 question — “Kidneys for Sale: Who Benefits?” — cuts through the theoretical tidiness to expose a more uncomfortable reality. When kidney markets exist, legal or illegal, the primary beneficiaries are rarely the desperate sellers or the dying recipients. The real winners, consistently documented across every existing kidney market, are the brokers, intermediaries, surgeons, and coordinators who extract the vast majority of value from transactions in which vulnerable people bear all the risk.
Understanding who actually benefits — and who bears the costs — is the essential starting point for any honest policy debate.
The Supply-Demand Crisis: Why the Debate Exists
The Numbers Behind the Shortage
The organ shortage that drives the kidney market debate is real and severe:
- Approximately 300,000 patients are registered on kidney transplant waiting lists worldwide, and only about one third receive a kidney transplant annually
- An estimated 2–7 million deaths occur annually because patients with kidney failure lack access to adequate treatment
- In the United States, average wait time for a kidney is 3.6 years; in Canada, up to 7 years
- Reports estimate that 75% of all illegal organ trading involves kidneys — the direct consequence of this unmet need
Each year, about 9,000 people in the US alone are removed from the kidney transplant waiting list because they die before being matched with a donor or become too sick to undergo the operation. This is the human reality that makes kidney market arguments emotionally compelling — and that market proponents deploy most effectively.
The Economic Logic of Kidney Compensation
The pro-market argument follows a clear economic logic. A government program to compensate kidney donors would have a monetary value of saving thousands of lives each year and reducing the suffering of hundreds of thousands more on dialysis of about $46 billion per year, and would save taxpayers about $12 billion a year.
Becker and Elías estimated that payments between $15,000 and $30,000 would eliminate the waiting list within a few years. If this arithmetic is correct, the case for regulated compensation appears overwhelming. So why does the ISN — and most of the global transplant community — oppose it? The answer lies in what the economic models omit.
Who Claims to Benefit: The Theoretical Case
The Seller: Autonomy and Economic Uplift
Proponents of regulated kidney sales argue that sellers benefit through:
- Economic improvement: escaping debt, funding education, starting a business
- Autonomous choice: respecting individuals’ right to make informed decisions about their own bodies
- Formalization: bringing transactions into the open where sellers receive proper medical care rather than exploitative black market conditions
The autonomy argument carries genuine philosophical weight. One essential field of tension is marked by the contention that although introducing well-regulated kidney markets would save more lives, it would also seem to violate and undermine the preservation of dignity. Proponents argue this dignity concern is paternalistic — that it denies poor people choices that wealthier people would be permitted to make.
The Recipient: Access and Survival
Recipients theoretically benefit through:
- Shorter waiting times — potentially saving their lives
- Reduced costs if markets drive down the total expense of transplantation
- Access for populations currently excluded from donation-based systems
Governments compensating kidney donors would likely increase the supply of kidneys and prevent the premature deaths of tens of thousands of patients with kidney failure each year. This is the strongest argument for compensation, and it deserves serious engagement.
Who Actually Benefits: The Empirical Reality
The Broker: The Primary Beneficiary
The empirical data from existing kidney markets — legal and illegal — consistently shows the same distribution of value:
An illicit transplant costs between $50,000 (kidney) and $290,000 (lung), of which the source (“donor”) gets very little; typically it is the intermediaries — brokers, surgeons — that benefit the most, paying a pittance to the source while charging the recipient an exorbitant fee. The “markup” varies between 500% to nearly 2,000%.
In documented trafficking cases, kidney sellers receive between $1,000 and $10,000 — while recipients pay $50,000–$150,000. The difference flows to brokers, corrupt surgeons, and logistics networks. Even in the most favorable documented cases, sellers receive less than 10% of the total transaction value.
The Seller: The Primary Risk-Bearer
Donors are poor, with most living below the poverty line. Most are illiterate and in low-paid manual jobs, their sole reason for donating not borne of altruism but to pay off debt. Sadly for the majority of donors, selling a kidney does not result in the significant economic benefit of which they dreamed. Often it is associated with a decline in general health.
The outcomes for kidney sellers across documented populations:
| Outcome | Promised | Actual |
| Payment received | Full agreed amount | Typically 30–70% withheld by brokers |
| Post-operative care | Medical follow-up | Rarely provided; sellers left without support |
| Economic outcome | Debt relief / new start | Most remain in poverty; debt often unresolved |
| Health impact | “No lasting effects” | Increased fatigue, reduced work capacity, chronic pain reported |
| Legal protection | Implied | None in illegal markets; limited in regulated ones |
| Psychological impact | Not discussed | Regret, stigma, and trauma frequently reported |
In Pakistan many individuals donate kidneys to release themselves from bonded slavery but have insufficient capital to make a new life and often return to debt.
The Poor Patient: Systematically Excluded
One of the most striking findings in the compensation debate is that poor patients — ostensibly among the intended beneficiaries of an expanded kidney supply — are systematically excluded from the benefits:
Poor people are under-represented as kidney transplant recipients: they account for 34 percent of patients newly diagnosed with end-stage kidney disease, but they receive just 6 percent of the nation’s kidney transplants.
Kidney markets, whether legal or illegal, do not correct this inequity — they amplify it. It arguably violates beneficence as well as principles of justice when arguing in favor of a market where poor people supply a crucial body part to people who are from wealthier countries and generally wealthier themselves.
The Iran Model: The Only “Natural Experiment”
What Iran’s Regulated System Shows
Iran has operated a government-regulated compensated kidney donation program since 1988 — the world’s only legal kidney market. Its outcomes provide the most relevant empirical test of regulated compensation claims:
Claimed successes:
- Iran eliminated its deceased-donor kidney waiting list — the program’s central achievement
- Sellers receive government compensation plus subsidized health insurance
- Transactions are formally registered and medically supervised
Documented problems:
- The number of individuals on a waiting list to receive a kidney currently exceeds 100,000 globally; adoption of commercial kidney transplantation in the Western world would have inevitable knock-on effects in developing countries.
- Studies of Iranian kidney sellers consistently show persistent poverty, health complaints, and regret at rates far exceeding altruistic donors
- The regulated market has not prevented an illegal parallel market from also operating
- Long-term follow-up of sellers remains inadequate by international standards
The Iran model demonstrates that regulation can formalize and medically supervise kidney transactions — but cannot resolve the fundamental asymmetry between economically desperate sellers and the intermediary networks that capture most of the transaction value.
The ISN’s Position: Why “Who Benefits?” Matters
The Declaration of Istanbul Standard
The Declaration of Istanbul on Organ Trafficking and Transplant Tourism, emerging from a 2008 summit convened by the Transplantation Society and the International Society of Nephrology, stated: “Organ trafficking and transplant tourism violate the principles of equity, justice and respect for human dignity and should be prohibited. Transplant commercialism targets impoverished and otherwise vulnerable donors leading to inequity and injustice.
The ISN’s 2019 “Kidneys for Sale: Who Benefits?” framing was deliberately provocative — intended to shift the debate from theoretical economic modeling to empirical accountability. The question is not whether a kidney market could benefit sellers and recipients under ideal conditions; it is whether it does in practice.
Alternatives That Actually Expand Supply Without Exploitation
The ISN and global nephrology community have identified supply-expansion strategies with evidence of effectiveness that do not require kidney markets:
- Opt-out deceased donor legislation: Spain’s presumed-consent system achieves ~47 donors per million population — among the world’s highest — without any market mechanism
- Kidney paired exchange programs: matching incompatible donor-recipient pairs creates new transplants from existing willing donors without compensation
- Non-directed altruistic donation: structured programs enabling strangers to donate kidneys altruistically have created “donation chains” completing 30+ transplants from a single initial donor
- Living donor expense reimbursement: removing financial barriers to donation (lost wages, travel costs) without creating a price signal that attracts economically desperate donors
- CKD prevention: reducing ESRD incidence is the most upstream intervention — every patient who does not reach ESRD is one fewer person on the waiting list
Conclusion
The question “Kidneys for Sale: Who Benefits?” deserves the honest answer that kidney markets — regulated or otherwise — have consistently failed to deliver on their promises to the people most cited as their beneficiaries. Poor people are also more likely to volunteer to sell their organs, and while some supporters of the organ trade argue that it helps lift some people out of poverty, evidence of this claim is hotly debated. In many cases, people who sell their organs in order to pay off debt do not manage to escape this debt and remain trapped in debt cycles.
The transplant shortage is real, the deaths on waiting lists are real, and the desperation of both potential sellers and potential recipients is real. These realities deserve serious, evidence-based responses — not theoretical market models that distribute benefits to intermediaries while distributing risks to the most vulnerable.
Your next steps as a patient, clinician, or engaged citizen:
- If you are on a kidney waiting list, ask your transplant team specifically about paired exchange programs — these have expanded dramatically in recent years and may offer a pathway to transplantation that does not require years of waiting
- Register as a deceased organ donor and discuss your wishes with family — in opt-in systems, family objection is the leading cause of donation failure even when the individual was registered
- Advocate for opt-out deceased donor legislation in your country — this is the single most evidence-supported supply-expansion intervention available
- If you are a nephrologist, familiarize yourself with the Declaration of Istanbul Custodian Group’s updated 2018 guidance — professional responsibility extends to not referring patients to centers or countries known for transplant commercialism
- Support policies that remove financial barriers to altruistic living donation — reimbursing donors for lost wages and travel costs is not a market; it is fairness, and it expands the donor pool without creating exploitation incentives
- Engage the “who benefits?” framework in policy discussions — demand empirical evidence about actual outcomes for sellers, not theoretical projections, before accepting market arguments at face value